The Chinese Academy of Sciences (CAS) has put forward the concept of building a national innovation system, and has successively implemented the Knowledge Innovation Project, Innovation 2020, the Pioneering Action Program and the Outline of Comprehensive and Deepening Reform, and put forward strategic research reports, such as “Embracing the Age of Knowledge Economy, and Building a National Innovation System Innovation for Development, Science and Technology Leading the Future, Innovation 2050: Science and Technology and China's Future, New Situation of Scientific and Technological Development and Strategic Choices for 2020, and other strategic research reports.

Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Medicine is an innovative international pharmaceutical enterprise focusing on the research, development, production and promotion of high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, neurological diseases and other areas, and it is one of the most innovative pharmaceutical leading enterprises in China.

Bristol-Myers is a global biotechnology company focused on the development and commercialization of innovative, affordable antineoplastic drugs with the goal of improving treatment outcomes and access to medicines for patients worldwide.

Cannon Chem is a leading international life science R&D service company. Since its inception in 2004, Cannon Chemical has been committed to its people and facilities, creating a system of R&D and manufacturing services for multi-therapeutic drug discovery, including small molecules, large molecules, and cellular and gene therapeutics, throughout the entire process of drug discovery, preclinical and clinical development. With operations in China, the U.S., and the U.K. and more than 20,000 employees, Cannon Chemical provides R&D solutions and maintains relationships with partners in North America, Europe, Japan, and China.

Shanghai Medicilon Biopharmaceuticals Co., Ltd. is a drug discovery and development outsourcing service company (CRO), which has established a comprehensive technical service platform in Shanghai in line with international standards, integrating compound synthesis, compound activity screening, structural biology,** chemical evaluation, pharmacokinetic evaluation, toxicology evaluation, formulation studies and new drug registration, and has been recognized by international drug regulatory authorities. MediSipia Pharmaceutical Technology (Shanghai) Co., Ltd. was founded in February 2008, focusing on preclinical pharmacokinetic and safety evaluation studies. MediSipia's animal testing facilities are accredited by AAALAC (Association for the Assessment and Accreditation of Animals International) and the China Food and Drug Administration GLP certificate, and have met the U.S. Food and Drug Administration GLP standards. Medicilon helps clients reach their goals faster with efficient and cost-effective one-stop professional services. Close

Established in 1997, under the philosophy of “making good medicines for China and repaying the world with good deeds”, Shiyi Pharmaceutical Holding Group Co., Ltd. has maintained double-digit growth in its main business indexes for many years through innovative development. Now it has developed into an internationalized innovative enterprise with 28,000 employees. Its Hong Kong-listed company was selected as a constituent stock of the Hang Seng Index, and on behalf of China Pharmaceutical, it was ranked 24th on the list of global pharmaceutical companies in terms of R&D pipeline size, serving patients all over the world.

Together, we are leading the way to life and health through science. We have a broad portfolio of scientific products, advanced drug discovery and manufacturing capabilities, and a fully integrated platform of CDMO and contract testing services for both traditional and novel pharmaceuticals. We are committed to creating a sustainable future for the next generation with innovative products, high-quality services and digital solutions for the benefit of the world.

WuXi AppTec provides integrated, end-to-end drug discovery and manufacturing services to the global pharmaceutical and life sciences industries, with operations in Asia, Europe and North America. Through its unique “CRDMO” and “CTDMO” business models, WuXi AppTec continuously lowers the threshold of R&D, helps clients improve R&D efficiency, and brings more breakthrough therapeutic solutions to patients, with services ranging from chemical R&D and manufacturing, biological research, preclinical testing and clinical trial R&D, precision medicine, and biotechnology, biological research, preclinical testing and clinical trial R&D, precision medicine R&D, testing and manufacturing, etc. In 2023, WuXi PharmaTech was rated AA in ESG (Environmental, Social and Governance) by MSCI for the third consecutive year. Currently, the company's empowerment platform is carrying the R&D and innovation projects of more than 6,000 partners from more than 30 countries around the world, and is committed to bringing more new and better medicines to patients around the globe and realizing the vision of “making the world free of hard-to-make medicines and hard-to-treat diseases” as soon as possible.